GSK receives European and CHMP approval for stem cell gene therapy
1st Apr 2016 15:40
(ShareCast News) - GlaxoSmithKline has been given encouraging support for a stem cell gene therapy that uses an individual patient's own cells to treat a very rare immunodeficiency disorder in children. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA),
Read moreGlaxoSmithKline to drop patents in world's poorest countries
31st Mar 2016 14:36
(ShareCast News) - London-listed pharmaceuticals giant GlaxoSmithKline said on Thursday that it is evolving its graduated approach to filing and enforcing patents so that IP protection reflects a country's wealth. In a statement ahead of a meeting of the UN High Level Panel on Access to Medicines, G
Read moreWednesday broker round-up
30th Mar 2016 14:53
(ShareCast News) - Inmarsat: Berenberg upgrades to hold with a target price of 890p. Next: Investec downgrades to sell, 5250p target, Jefferies reiterates hold with a target price of 5100p, JP Morgan stays at neutral with a target of 6370p and HSBC keeps at hold, 6260p target. Glaxosmithkline: Citi
Read moreCitigroup ups view on GlaxoSmithKline back to buy
30th Mar 2016 09:21
(ShareCast News) - Analysts at Citi moved to a 'buy' recommendation on shares of GlaxoSmithKline for the first time in three years, telling clients the group´s drug pipeline was "credible and undervalued" and that many of the broker´s previous concerns were now being addressed. The pharma group´s on
Read moreFriday newspaper round-up: Sainsbury's, Hinkley Point, Oil, GSK
18th Mar 2016 07:13
(ShareCast News) - The new administrators of Libor are overhauling the way it is calculated, reducing its reliance on banker estimates in an attempt to restore faith in the scandal-hit rate. US markets operator Intercontinental Exchange took over administration of the London Interbank Offered Rate i
Read moreGSK's Advair Diskus proves non-inferior in paediatric safety study
17th Mar 2016 07:39
(ShareCast News) - A study to determine the safety GlaxoSmithKline's combined asthma treatment in children has hit its primary end point. Monitoring the effects on 6,250 children aged 4-11 found GSK's Advair Diskus, a combination of the long acting beta2-agonist (LABA), salmeterol and inhaled cortic
Read moreLondon pre-open: Stocks seen a little higher ahead of BoE announcement
17th Mar 2016 07:27
(ShareCast News) - London stocks are set to open a little higher on Thursday as investors digest the Federal Reserve's decision to stand pat on rates and look to the Bank of England's latest policy announcement. The FTSE 100 is seen starting 15 points higher than Wednesday's close at 6,190. The BoE
Read moreGlaxoSmithKline's Witty to retire in early 2017
17th Mar 2016 07:06
(ShareCast News) - Bowing to pressure from institutional shareholders, GlaxoSmithKline chief executive Andrew Witty has decided to retire from the company at the end of March next year. The FTSE 100 drug maker will now conduct a formal search for a successor, though reports have indicated it has bee
Read moreGSK reveals "significant improvement" in Nucala severe asthma tests
8th Mar 2016 12:22
(ShareCast News) - GlaxoSmithKline has reported encouraging data on the effect of its Nucala drug on severe asthma sufferers. GSK presented results at the American Academy of Allergy, Asthma & Immunology (AAAAI) late on Monday that showed patients with severe asthma experienced a "significant improv
Read moreGlaxo's Advair Diskus study results published by NEJM
7th Mar 2016 07:46
(ShareCast News) - Results from GlaxoSmithKline's long-term safety study of Advair Diskus for the treatment of adults and adolescents with asthma have been published by the New England Journal of Medicine. Kate Knobil, chief medical officer of pharmaceuticals at GSK said: "We are pleased that this s
Read moreLondon pre-open: Stocks seen lower on profit-taking
7th Mar 2016 07:15
(ShareCast News) - London stocks are expected to open a little weaker on Monday as investors look to book some profits following recent gains. The FTSE 100 is seen starting 29 points lower than Friday's close at 6,170. Michael Hewson, chief market analyst at CMC Markets, said: "Despite this recover
Read moreSunday newspaper round-up: Pound, GSK, Sainsbury's, HSBC
28th Feb 2016 17:29
(ShareCast News) - Sterling will fall to $1.28 by the end of 2016, its lowest level against the US dollar in three decades, currency strategists have cautioned. If Britain votes to leave the European Union the fall will be even worse, the Sunday Telegraph reported that Deutsche Bank analysts saw a f
Read moreMonday broker round-up
22nd Feb 2016 13:49
(ShareCast News) - Coca-Cola Hbc: JP Morgan reiterates neutral with a target price of 1450p, Nomura stays at buy with a 1330p target and Deutsche Bank keeps at hold with a target price of 1500p. Standard Life: JP Morgan keeps at overweight with a target of 465p and Deutsche Bank reiterates buy, 415p
Read moreSunday newspaper round-up: GSK, Sainsbury's, BT, Imagination Technologies
21st Feb 2016 17:23
(ShareCast News) - Financial institutions in the City of London are fairly pleased with David Cameron's agreement with the European Union ahead of June's referendum as it looks to have secured the Square Mile from excessive further Brussels red tape. A potentially painful sticking point has been avo
Read moreFriday broker round-up
12th Feb 2016 15:24
(ShareCast News) - Cambian Group: Berenberg downgrades to hold with a target of 60p. Shaftesbury: Credit Suisse upgrades to outperform with a target price of 945p. Acacia Mining: UBS and Deutsche Bank reiterate buy with a target of 275p and 280p respectively. Ashmore: Citigroup stays at buy with a
Read more